Aerovate Therapeutics Company
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.
Connections from
Funding Status:
IPO
Industry:
BioTech
Technology:
Anti-infective Drugs
Founded Date:
2019-01-01
Headquarters:
Boston, Massachusetts, United States
Total Funding:
72600000
Last Funding Type:
Series A
Employee Number:
1-10